Test-retest reproducibility of [F-18]fluciclatide PET imaging in subjects with solid tumors
Rakesh Sharma(Wayne State University), Eric O. Aboagye(Imperial College London), R. Parameswaran, Norbert Avril(University Hospitals of Cleveland), J-H Ryu, M J O'Doherty, J. D. Lee, R. Charles Coombes(Imperial College London), Henrik Lindman(Uppsala University), Fergus Gleeson(Churchill Hospital), M.P. Miller, AM Groves, Kumar Kallur, Carolyn L. Paterson, K. H. Lee
European Journal of Nuclear Medicine and Molecular Imaging
October 1, 2012
Cited by 1
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504